We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
(+21%)
Cap. Flow
+$48.2M
Cap. Flow
% of AUM
4.04%
Top 10 Holdings %
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$22.4M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$14.4M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$13.8M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$11.6M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$24.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$18.9M |
| 3 |
Arrowhead Research
ARWR
|
+$18.4M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$14.7M |
| 5 |
HCA Healthcare
HCA
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.07% |
| 2 | Financials | 0.1% |
| 3 | Energy | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $120M | 10.07% |
14,439,444
+2,100,000
| +17% | +$14.4M |
|
|
2
Neurocrine Biosciences
NBIX
$18.3B
| $79.6M | 6.68% |
3,565,267
-1,000,000
| -22% | -$18.9M |
|
3
Talphera
TLPH
$68.5M
| $44.2M | 3.71% |
328,703
| – | – |
|
4
Sarepta Therapeutics
SRPT
$1.66B
| $40.7M | 3.41% |
2,812,352
+215,661
| +8% | +$3.65M |
|
|
RLYP
5
DELISTED
RELYPSA INC COM
RLYP
| $38.2M | 3.2% |
1,239,142
+476,437
| +62% | +$11.3M |
|
|
6
PUT
Neurocrine Biosciences
NBIX
$18.3B
| $35.7M | 3% |
1,600,000
+947,000
| +145% | +$17.9M |
|
|
RCPT
7
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $35.7M | 2.99% |
291,394
-22,200
| -7% | -$2.25M |
|
8
PTC Therapeutics
PTCT
$6.22B
| $34.8M | 2.92% |
671,736
| – | – |
|
9
Acadia Pharmaceuticals
ACAD
$4.52B
| $34.7M | 2.91% |
1,093,281
-4,633
| -0.4% | -$131K |
|
|
TSRO
10
DELISTED
TESARO, Inc.
TSRO
| $32.9M | 2.76% |
883,359
+175,075
| +25% | +$5.4M |
|
11
Xencor
XNCR
$1.47B
| $30.9M | 2.59% |
1,927,171
+4,464
| +0.2% | +$51.8K |
|
|
DYAX
12
DELISTED
DYAX CORPORATION
DYAX
| $26M | 2.18% |
1,852,000
-983,498
| -35% | -$12.3M |
|
|
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $24.1M | 2.02% |
+104,640
| New | +$22.4M |
|
14
Travere Therapeutics
TVTX
$5.26B
| $23.8M | 1.99% |
1,940,725
+561,588
| +41% | +$5.81M |
|
|
TARO
15
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $22.8M | 1.91% |
154,028
+13,093
| +9% | +$1.92M |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $20.6M | 1.73% |
+17,370
| New | +$11.6M |
|
|
ARAV
17
DELISTED
Aravive, Inc. Common Stock
ARAV
| $19.7M | 1.66% |
155,195
+73,985
| +91% | +$8.65M |
|
|
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $19.3M | 1.62% |
429,386
-90,779
| -17% | -$3.81M |
|
|
19
ANI Pharmaceuticals
ANIP
$1.85B
| $17.6M | 1.48% |
+312,500
| New | +$13.8M |
|
|
AGN
20
DELISTED
Allergan Inc
AGN
| $17.6M | 1.47% |
82,583
+32,583
| +65% | +$6.48M |
|
21
Zimmer Biomet
ZBH
$18.7B
| $17.5M | 1.47% |
158,716
-101,359
| -39% | -$10.7M |
|
|
CELG
22
DELISTED
Celgene Corp
CELG
| $16.4M | 1.37% |
146,567
-230,881
| -61% | -$24.3M |
|
|
OTIC
23
DELISTED
Otonomy, Inc.
OTIC
| $15.1M | 1.27% |
454,306
-383,094
| -46% | -$10.3M |
|
|
24
Vertex Pharmaceuticals
VRTX
$124B
| $13.1M | 1.1% |
110,000
-130,142
| -54% | -$14.7M |
|
|
NEPT
25
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $12.8M | 1.08% |
4,822
+36
| +0.8% | +$90.2K |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2014 Portfolio in Review
As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.
On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.
- Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
- Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
- Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
- Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
- Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
- Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
- Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.
Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.